The proposal entitled “Development of efficient immunoglobulin G analytical method for investigating autoantibody biomarkers for pancreatic disease” had been submitted to MOST and was funded for the first year (105-2320-B-038-066-). With good progress and pilot results for this study, we would like to submit the proposal for two consecutive years. The proposal was revised based on our current results, reviewer’s comments, and the innovations from literature surveys. Autoantibodies have been reported as potential diagnostic or prognostic biomarkers for different kinds of diseases. Approaches to investigation of autoantibodies include screening antibodies from patient serum with autoantigen library, and analyzing comprehensive antibody repertoire by B cell gene sequencing, or by IgG variable region peptide analysis with proteomics method. Pancreatic cancer is the fourth leading cause of cancer deaths with 5-years survival rate less than 5 %, which is due to the difficulty of early diagnosis of the disease. Autoimmune pancreatitis is an IgG4 related disease with unclear pathogenesis. The clinical symptoms and imaging features of autoimmune pancreatitis are mimic to pancreatic cancer, which makes the differential diagnosis of the two diseases challenging. In this project, we aim to investigate and find out specific autoantibodies or IgG variable region peptides to use them as biomarkers for patients with pancreatic cancer and autoimmune pancreatitis. To analyze hundreds of clinical samples, we started to develop efficient method for IgG/IgG4 variable region peptides analysis. Specific aims of this project to achieve biomarker investigation include: (1) Apply the developed method to IgG variable region analysis in clinical samples. We also added two novel specific aims: (2) Purify IgG4 and analyze the variable region peptides. (3) Purify autoantibodies by using potential disease-related autoantigens, and analyze the variable region peptides. The expected results of this project will not only provide novel analytical platforms for IgG investigation, but also help to achieve accurate and early diagnosis of pancreatic diseases with the novel biomarkers.
|Effective start/end date||8/1/18 → 7/1/19|
- IgG variable region
- pancreatic cancer
- autoimmune pancreatitis